Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17940959 | 0.99 | GAA (0.47) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL6233467 | 0.99 | GAA (0.47) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL17940927 | 0.99 | GAA (0.47) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL23636404 | 0.99 | GAA (0.47) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL21479430 | 0.99 | GAA (0.47) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL23636475 | 0.99 | GAA (0.47) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL17941052 | 0.95 | GAA (0.44) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL31425361 | 0.92 | GAA (0.44) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL4589079 | 0.92 | GAA (0.46) | GAANPSR1STAT3ALDH1A1LMNA | |
| SCHEMBL17940989 | 0.91 | GAA (0.45) | GAANPSR1STAT3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230078913-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA INC. (CA) | 2023-03-16 | — | — | US | claimed |
| CN-114269331-A | Androgen receptor modulators and methods of use as proteolytic targeting chimeric ligands | 埃萨制药股份有限公司 | 2022-04-01 | — | — | CN | claimed |
| EP-3946292-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | Essa Pharma, Inc. (CA) | 2022-02-09 | — | — | EP | claimed |
| WO-2020198711-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA, INC. (CA) | 2020-10-01 | — | — | WO | claimed |
| EP-3658548-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | claimed |
| CN-111212835-A | Compounds and methods for targeted degradation of androgen receptors | 阿尔维纳斯运营股份有限公司 | 2020-05-29 | — | — | CN | claimed |
| WO-2019023553-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2019-01-31 | — | — | WO | claimed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | claimed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3526202-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| EP-1718599-B1 | SYNTHESIS OF STERICALLY HINDERED SECONDARY AMINOETHER ALCOHOLS | EXXONMOBIL RES & ENG CO (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-1718599-A4 | SYNTHESIS OF STERICALLY HINDERED SECONDARY AMINOETHER ALCOHOLS | EXXONMOBIL RES & ENG CO (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1718599-A1 | SYNTHESIS OF STERICALLY HINDERED SECONDARY AMINOETHER ALCOHOLS | ExxonMobil Research and Engineering Company (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082835-A1 | SYNTHESIS OF STERICALLY HINDERED SECONDARY AMINOETHER ALCOHOLS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-5834454-A | TREATMENT OF ANGINA, ISCHEMIA, ARRHYTHMIA | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078913-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | AR, PSMA1, SHBG | GAA 1820/4885NPSR1 880/4885STAT3 2114/4885 |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | GAA 1291/4885NPSR1 466/4885STAT3 3347/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | GAA 1071/4885NPSR1 522/4885STAT3 3210/4885 |
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | PCNA, DNMT1, DNMT3B | GAA 1087/4885NPSR1 4679/4885STAT3 1898/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | GAA 1071/4885NPSR1 522/4885STAT3 3210/4885 |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | GAA 1082/4885NPSR1 1057/4885STAT3 3560/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | GAA 1082/4885NPSR1 1057/4885STAT3 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.